|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS: | |||||||||||||||||
| Cash and due from banks | |||||||||||||||||
| Federal funds sold | |||||||||||||||||
| Total cash and cash equivalents | |||||||||||||||||
| Available for sale, at fair value | |||||||||||||||||
| Held to maturity, at amortized cost, net of allowance for credit losses of $75 and $55 at March 31, 2024 and December 31, 2023, respectively | |||||||||||||||||
| Total investment securities | |||||||||||||||||
| Loans, net of allowance for credit losses of $15,981 and $16,028 at March 31, 2024 and December 31, 2023, respectively | |||||||||||||||||
| Premises and equipment, net | |||||||||||||||||
| Bank owned life insurance (BOLI) | |||||||||||||||||
| Goodwill and other intangible assets | |||||||||||||||||
| Accrued interest receivable and other assets | |||||||||||||||||
| Total assets | |||||||||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY: | |||||||||||||||||
| Deposits | |||||||||||||||||
| Noninterest-bearing | |||||||||||||||||
| Interest-bearing | |||||||||||||||||
| Total deposits | |||||||||||||||||
| Other borrowings | |||||||||||||||||
| Junior subordinated debt securities | |||||||||||||||||
| Accrued interest payable and other liabilities | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| Shareholders' equity | |||||||||||||||||
| Preferred stock, no par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | |||||||||||||||||
| Common stock, no par value; 40,000,000 shares authorized; 8,436,732 and 8,402,482 issued and outstanding at March 31, 2024 and December 31, 2023, respectively | |||||||||||||||||
| Retained earnings | |||||||||||||||||
| Accumulated other comprehensive loss, net of taxes | |||||||||||||||||
| Total shareholders' equity | |||||||||||||||||
| Total liabilities and shareholders' equity |
Loading...